Skip to content
Head to head

Precigen vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: PGEN · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

PGEN -14.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
PGENVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price4.21515.02
Change today+1.20%-1.08%
1-year return+7.9%+22.0%
Market cap$1.51B$130.58B
52-week range3.04 – 8.98412.27 – 568.67
Valuation
P/E (TTM)38.2733.14
P/E percentile, own 5-yr range100th99th
P/B17.996.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.3715.32
Net profit (TTM)$-491.21M$3.88B
Revenue (TTM)$156.94M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+2437.6%+11.8%
Gross margin91.4%85.5%
Operating margin21.4%33.1%
Net margin15.6%30.7%
Free cash flow (TTM)$-74.32M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership74.8%96.8%
Insider activity (12mo)25 buy / 25 sell28 buy / 22 sell
Short interest (% of float)12.5%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$14 (+233%)$624 (+21%)
StockVane view
StockVane Quant RatingD (39)C (68)
Company
Employees476,400
Founded19981989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.